Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:A61K39/42

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/105772BISPECIFIC ANTIBODY HAVING NEUTRALIZING ACTIVITY AGAINST CORONAVIRUS, AND USE THEREOF
WO 27.05.2022
Int.Class C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
Appl.No PCT/CN2021/131080 Applicant SANYOU BIOPHARMACEUTICALS CO., LTD. Inventor LANG, Guojun
Provided are a bispecific antibody having a neutralizing activity against a coronavirus, and a use thereof. A neutralizing antibody which is against a coronavirus S protein and blocks the binding of the coronavirus S proteins to an ACE 2 receptor is provided to prevent and treat coronaviruses. Specifically provided is an antibody or polypeptide complex specifically binding to a coronavirus S protein, comprising: (a) a first epitope binding moiety comprising a heavy chain variable region VH and a light chain variable region VL, wherein the VH and VL form an antigen binding domain specifically binding to a first epitope of an S protein; and (b) a second epitope binding moiety comprising a single-domain antibody or a VHH fragment thereof specifically binding to a second epitope of the S protein, wherein the first and second epitope binding portions are fused to each other and are not identical to each other. Also provided is a polynucleotide for encoding an antibody or a polypeptide complex and a host cell comprising same, and a method for preparing an antibody or a polypeptide complex. The antibody or polypeptide complex can be used for preventing, treating, diagnosing, and/or detecting coronaviruses.
2.WO/2022/104918BISPECIFIC ANTIBODY HAVING NEUTRALIZING ACTIVITY AGAINST CORONAVIRUS, AND USE THEREOF
WO 27.05.2022
Int.Class C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
Appl.No PCT/CN2020/133194 Applicant SANYOU BIOPHARMACEUTICALS CO., LTD. Inventor LANG, Guojun
A bispecific antibody having neutralizing activity against coronavirus and the use thereof. Provided is a neutralizing antibody against a coronavirus S protein and for blocking same from binding to an ACE2 receptor to prevent and treat coronavirus. Specifically, the present invention relates to an antibody or a polypeptide complex that specifically binds to the coronavirus S protein, which antibody or polypeptide complex comprises: (a) a first epitope binding moiety, which comprises a heavy chain variable region VH and a light chain variable region VL, wherein VH and VL form an antigen binding domain of a first epitope that specifically binds to the S protein; and (b) a second epitope binding moiety, which comprises a single-domain antibody of a second epitope that specifically binds to the S protein, or a VHH fragment thereof, wherein the first and second epitope binding moieties are fused to each other and are different from each other. The present invention also relates to a polynucleotide encoding the antibody or polypeptide complex, a host cell comprising same, and a method for preparing the antibody or polypeptide complex. The antibody or polypeptide complex can be used to prevent, treat, diagnose and/or detect coronavirus.
3.WO/2022/109443SINGLE-CHAIN ANTIBODY AGAINST FLAVIVIRUS NS1 PROTEIN
WO 27.05.2022
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/US2021/060468 Applicant THE REGENTS OF THE UNIVERSITY OF MICHIGAN Inventor SMITH, Janet L.
The disclosure is directed to binding agents, e.g., a single chain variable fragment (scFv) that specifically binds to a flavivirus NS1 protein, as well as compositions comprising the binding agent and a method of using such compositions to induce an immune response against a flavivirus (e.g., a dengue virus). The disclosure also provides a conjugate comprising the binding agent, and a recombinant NS1 antigen.
4.WO/2022/109155POLYNUCLEOTIDE NANOSTRUCTURES FOR DETECTING VIRAL INFECTIONS AND OTHER DISEASES
WO 27.05.2022
Int.Class C12Q 1/6816
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6813Hybridisation assays
6816characterised by the detection means
Appl.No PCT/US2021/059919 Applicant ATOM BIOWORKS, INC. Inventor WANG, Xing
The present disclosure relates to polynucleotide nanostructures and techniques that use polynucleotide nanostructures as bimolecular recognition entities for detecting viral infections, e.g. Covid-19, and other diseases. For example, an artificial biopolymer complex can include a network of polynucleotides including structural units connected to one another via a series of arms and junctions, e.g. in the form of a DNA Star. Intersections of three or more arms form the junctions at a predetermined distance from one another. The artificial biopolymer complex further includes binders, e.g. aptamers, attached to the network of polynucleotides that can bind to antigens of a target analyte. The binders are attached at loci on one or more of the arms forming the junctions. The loci are separated by predetermined inter¬ binder distances such that the binders are positioned on the network of polynucleotides in a predetermined two-dimensional or three- dimensional spatial pattern that matches a two-dimensional or three- dimensional spatial pattern of the antigens on the target analyte. The nucleic acid oligonucleotides, e.g. the aptamers, from which the nanostructure is formed may be labelled with fluorophores and/or quenchers to detect the binding to a target.
5.WO/2022/103758METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
WO 19.05.2022
Int.Class C12Q 1/70
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
70involving virus or bacteriophage
Appl.No PCT/US2021/058638 Applicant GILEAD SCIENCES, INC. Inventor MARTIN, Stephen R.
Provided are methods for identifying patient populations infected with HIV that can be targeted by antibodies that bind to HIV gp120 CD4 binding site (CD4bs) region.
6.WO/2022/103871THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF COVID-19
WO 19.05.2022
Int.Class A61K 35/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
20Milk; Whey; Colostrum
Appl.No PCT/US2021/058831 Applicant WYOMINGV IMMUNE, INC. Inventor ROBINSON, Gary
The present invention provides tor compositions and methods for treating SARS Co-V2 infection in a patient in need thereof, in particular, the invention provides pharmaceutical compositions comprising monoclonal antibodies, polyclonal antibodies, anti-ideotype antibodies, or mixtures of such antibodies, directed against SARS Co-V2 antigens. Thus, the pharmaceutical compositions and formulations of the invention may be used to deliver antibody therapeutics to the patient for treatment of SARS Co-V2 infection.
7.WO/2022/101805HYPERIMMUNE GLOBULINS FOR TREATMENT OF CHIKUNGUNYA VIRUS INFECTIONS
WO 19.05.2022
Int.Class A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
Appl.No PCT/IB2021/060416 Applicant EMERGENT BIOSOLUTIONS CANADA INC. Inventor NYKIFORUK, Cory
The present disclosure is directed to methods of using mixtures of anti-Chikungunya virus (CHIKV) antibodies and/or antigen-binding fragments thereof to treat CHIKV infections in human patients.
8.WO/2022/098525INTRANASAL ANTIVIRAL THERAPY FOR MUCOSAL PROTECTION AGAINST VIRUS INFECTIONS
WO 12.05.2022
Int.Class A61K 31/717
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
716Glucans
717Celluloses
Appl.No PCT/US2021/056392 Applicant BRAVADO PHARMACEUTICALS, LLC Inventor MCMILLAN, Brian
A topical intranasal antiviral composition for protecting against virus infections. The composition comprises an antigen binder and a pharmaceutical suspender material to allow effective delivery into the nasal cavity. Examples of materials that could be used in the pharmaceutical suspender are microcrystalline cellulose or sodium carboxymethylcellulose (Na∙CMC). One particular target for the antigen binder could be SARS-CoV-2. For example, the antigen binder could target the S1 subunit of SARS-CoV-2. The composition could be made by a process in which the pharmaceutical vehicle is prepared, and then the antigen binder is added to the pharmaceutical vehicle to make a bioactive mixture, and then adding solid sodium chloride to the bioactive mixture. Also disclosed are methods of protection against virus infection using the intranasal antiviral composition. For example, in the case of SARS-CoV-2, the antigen binder would block the virus particles from attaching to ACE2 receptors on host cells of the nasal mucosa or nasopharynx. This blocking action would protect against virus infection.
9.WO/2022/095045SARS-COV-2 ANTIBODY AND APPLICATION THEREOF
WO 12.05.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/CN2020/127587 Applicant SHANGHAI JEMINCARE PHARMACEUTICAL CO., LTD. Inventor GU, Chunyin
A SARS-CoV-2 antibody and an application thereof. The SARS-CoV-2 antibody has one or more of the following properties: blocking the binding of an S protein RBD of SARS-CoV-2 or a mutant thereof with human ACE2; specifically binding to the S protein RBD of SARS-CoV-2 or a mutant thereof by using a very low KD value; and having SARS-CoV-2 neutralizing activity. Further provided are a preparation method related to the SARS-CoV-2 antibody are also provided and an application thereof.
10.WO/2022/099187SARS-COV-2 ANTIGEN-BINDING PROTEINS AND USES THEREOF
WO 12.05.2022
Int.Class A61P 11/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
Appl.No PCT/US2021/058593 Applicant PRESIDENT AND FELLOWS OF HARVARD COLLEGE Inventor ABRAHAM, Jonathan
The present invention provides severe acute respiratory syndrome coronavirus (SARS-CoV), e.g., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen- binding proteins, pharmaceutical compositions, and methods of use thereof to passively immunize and treat subjects having or at risk of having a SARS-CoV, e.g., SARS-CoV-2, infection.